美国研究综述-HCA 医疗保健、Ncino、Progyny

路透中文12-02

美国研究综述-HCA 医疗保健、Ncino、<a href="https://laohu8.com/S/PGNY">Progyny</a>

路透社12月2日 - 华尔街证券分析师周一调整了对包括 HCA Healthcare、Ncino 和 Progyny 在内的几家美国上市公司的评级和目标价。

要闻

* HCA Healthcare Inc HCA.N：摩根大通将目标价从379美元上调至380美元

* Ncino Inc NCNO.O：KBW将目标价从41美元上调至49美元

* Progyny Inc PGNY.O：摩根大通将其评级从 "增持 "下调至 "中性"。

以下是路透社周一报导的美国公司研究报告摘要。股票条目按字母顺序排列。

* Ardent Health Partners Inc ARDT.N：摩根大通将目标价从19美元上调至20美元

* HCA Healthcare Inc HCA.N：摩根大通将目标价从 379 美元上调至 380 美元

* Ncino Inc NCNO.O：KBW将目标价从41美元上调至49美元

* Progyny Inc PGNY.O：摩根大通将目标价从22美元下调至17美元

* Progyny Inc PGNY.O：摩根大通将其评级从 "增持 "下调至 "中性"。

* Tenet Healthcare Corp THC.N：摩根大通将目标价从172美元上调至175美元

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2488647428?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-02 15:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488647428","market":"us","top_or_hot":-1,"title":"美国研究综述-HCA 医疗保健、Ncino、Progyny","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>美国研究综述-HCA 医疗保健、Ncino、<a href=\"https://laohu8.com/S/PGNY\">Progyny</a></title></head><body><p><span>路透社12月2日</span><span> - </span>华尔街证券分析师周一调整了对包括 HCA Healthcare、Ncino 和 Progyny 在内的几家美国上市公司的评级和目标价。 </p><p> 要闻 </p><table><tbody><tr><td><p><span> * HCA Healthcare Inc <span>HCA.N</span>：<a href=\"https://laohu8.com/S/JPM\">摩根大通</a>将目标价从379美元上调至380美元</span></p></td></tr><tr><td><p><span> * Ncino Inc <span>NCNO.O</span>：KBW将目标价从41美元上调至49美元</span></p></td></tr><tr><td><p><span> * Progyny Inc <span>PGNY.O</span>：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。</span></p></td></tr></tbody></table><p>以下是路透社周一报导的美国公司研究报告摘要。股票条目按字母顺序排列。 </p><table><tbody><tr><td><p><span> * Ardent Health Partners Inc <span>ARDT.N</span>：摩根大通将目标价从19美元上调至20美元</span></p></td></tr><tr><td><p><span> * HCA Healthcare Inc <span>HCA.N</span>：摩根大通将目标价从 379 美元上调至 380 美元</span></p></td></tr><tr><td><p><span> * Ncino Inc <span>NCNO.O</span>：KBW将目标价从41美元上调至49美元</span></p></td></tr><tr><td><p><span> * Progyny Inc <span>PGNY.O</span>：摩根大通将目标价从22美元下调至17美元</span></p></td></tr><tr><td><p><span> * Progyny Inc <span>PGNY.O</span>：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。</span></p></td></tr><tr><td><p><span> * Tenet Healthcare Corp <span>THC.N</span>：摩根大通将目标价从172美元上调至175美元</span></p></td></tr></tbody></table><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美国研究综述-HCA 医疗保健、Ncino、Progyny</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美国研究综述-HCA 医疗保健、Ncino、Progyny\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-02 15:37 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nL3T3N30G2:1><strong>路透中文</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美国研究综述-HCA 医疗保健、Ncino、Progyny路透社12月2日 - 华尔街证券分析师周一调整了对包括 HCA Healthcare、Ncino 和 Progyny 在内的几家美国上市公司的评级和目标价。  要闻  * HCA Healthcare Inc HCA.N：摩根大通将目标价从379美元上调至380美元 * Ncino Inc NCNO.O：KBW将目标价从41美元上调至49...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nL3T3N30G2:1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0648000940.SGD","symbol_name":"Natixis Harris Associates Global Equity RA SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nL3T3N30G2:1","article_id":"2488647428","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488647428","pubTimestamp":1733125071,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"美国研究综述-HCA 医疗保健、Ncino、Progyny路透社12月2日 - 华尔街证券分析师周一调整了对包括 HCA Healthcare、Ncino 和 Progyny 在内的几家美国上市公司的评级和目标价。要闻  * HCA Healthcare Inc HCA.N：摩根大通将目标价从379美元上调至380美元 * Ncino Inc NCNO.O：KBW将目标价从41美元上调至49美元 * Progyny Inc PGNY.O：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","THC":"泰尼特","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4185":"保健护理机构","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","HCA":"HCA控股","NCNO":"nCino","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","PGNY":"Progyny","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4023":"应用软件","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","BK4225":"医疗保健房地产信托","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","BK4585":"ETF&股票定投概念","BK4203":"医疗保健房地产投资信托","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","VTR":"芬塔公司","ARDT":"Ardent Health Partners (2024 New Filing)","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4588":"碎股","BK4154":"管理型保健护理","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H"},"translate_title":"A review of US studies-HCA Healthcare, Ncino, Progyny","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTR":0.9,"THC":0.9,"ARDT":0.9,"PGNY":0.9,"HCA":0.9,"NCNO":0.9},"content_text":"美国研究综述-HCA 医疗保健、Ncino、Progyny路透社12月2日 - 华尔街证券分析师周一调整了对包括 HCA Healthcare、Ncino 和 Progyny 在内的几家美国上市公司的评级和目标价。  要闻  * HCA Healthcare Inc HCA.N：摩根大通将目标价从379美元上调至380美元 * Ncino Inc NCNO.O：KBW将目标价从41美元上调至49美元 * Progyny Inc PGNY.O：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。以下是路透社周一报导的美国公司研究报告摘要。股票条目按字母顺序排列。  * Ardent Health Partners Inc ARDT.N：摩根大通将目标价从19美元上调至20美元 * HCA Healthcare Inc HCA.N：摩根大通将目标价从 379 美元上调至 380 美元 * Ncino Inc NCNO.O：KBW将目标价从41美元上调至49美元 * Progyny Inc PGNY.O：摩根大通将目标价从22美元下调至17美元 * Progyny Inc PGNY.O：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。 * Tenet Healthcare Corp THC.N：摩根大通将目标价从172美元上调至175美元(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488647428"}